siRNA · Cardiometabolic
AR-310
Liver-targeted siRNAPlaceholder
A GalNAc-conjugated siRNA designed to silence a liver gene linked by human genetics to cardiometabolic risk.
Development stage
- Discovery
- Lead optimisation
- Preclinical
- Clinical
Scientific rationale
- Loss-of-function human genetics supports a favourable safety profile for knock-down.
- Sequence models ranked candidates for potency and predicted off-target seed matches.